IFM, Staying Small, Raises (Merely) $55.5M, Promotes Former Novartis Exec to CEO

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

IFM Nails Second Big Deal, Selling NLRP3 Inhibitors to Novartis for $310M Upfront